Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Indonesia’s R&D and healthcare preparedness aids in clinical trials of COVID-19 vaccine

Indonesia has been looking to secure access to candidate vaccines with local companies seeking cooperation with producers as well as the Coalition for Epidemic Preparedness Innovations (CEPI).

For a longer-term, self-sufficient strategy, a national consortium under the Research and Technology Ministry is working on developing its own vaccine, helmed by the Eijkman Institute for Molecular Biology. The vaccine will be named after Indonesia’s flag colors, Merah Putih, or red and white.

The Merah Putih vaccine was now entering the “critical” process that would “determine the success of the vaccine in the future”.

The development is testimony to Indonesian’s tech progress as well as their investment in technology in various fields, including healthcare, research and IT infrastructure.

Minister for Research and Technology/Chairman of National Agency for Research and Innovation, Bambang Brodjonegoro said they are currently building the organizational structure of his ministry to integrate the Research, Development, Assessment and Application (Litbangjirap).

This is to ensure the technological readiness from stage 1 to 9 to downstream the research outputs and tighten the academic researchers and industries relationships.

The minster felt a super tax deduction policy for R&D companies, both multinational and domestic, would be an incentive to invest more in Indonesia.

Various facilities of research, development, assessment and application in the Research Centre for Science and Technology (Puspiptek) have been in place for some time.

The Centre of Research, Development, Assessment and Application Agency for the Assessment and Application of Technology (BPPT) and the Nation Standardization Agency of Indonesia (BSN) are being developed continuously so they could be used by the industries, research institutions, universities and public.

Both facilities of BPPT and BSN are just two areas of the entire Puspiptek complex, in addition to the facilities managed by Indonesian Institute of Sciences (LIPI), National Nuclear Energy Agency (BATAN), and the Ministry of Environment and Forestry.

At the end of 2019, the Minister for Research and Technology/Chairman of National Agency for Research and Innovation, Bambang Brodjonegoro, officially launched the National Center for Stem Cells and Metabolites Production.

The institution, established in partnership with Medical School of University of Indonesia, will give stem cell treatments for various degenerative diseases with more affordable price for patients compared with similar treatments abroad.

In the meantime, Indonesian scientists are set to start the phase III clinical trials of a potential COVID-19 vaccine this coming week in six different locations in the West Java provincial capital of Bandung.

Padjajaran University (Unpad) Medical School professor Kusnandi Rusmil, the clinical trial research team leader, said the human trials would commence on Aug. 11

Food and Drug Supervisory Agency (BPOM) head Penny Kusumastuti Lukito said the agency had been working closely with the clinical trial research team to make sure the phase III trials could be carried out safely and in an ethically appropriate manner.

So far, about 800 volunteers have registered for the trials which is half the number of people that was being aimed for.

The team was looking for a total of 1,620 volunteers and volunteer registrations would be open until Aug. 31.

The trials are expected to finish in about 6 months at the earliest.

State-owned pharmaceutical holding company PT Bio Farma said the company was currently conducting a stability test on the vaccine in its laboratory facilities.

Bio Farma is planning to ramp up production capacity and be ready to produce 250 million doses of the vaccine per year by December.

The company also planned to invest loan funds of at least Rp 1.3 trillion (US$88 million) in the development of infrastructure and human resources in the research and production units.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.